ORABASE HCA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORABASE HCA (ORABASE HCA).
Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation. Orabase (hydroxypropyl cellulose) forms a protective barrier over oral lesions.
| Metabolism | Hydrocortisone is metabolized primarily in the liver via 11β-hydroxysteroid dehydrogenase; minor metabolism by CYP3A4. Orabase is not metabolized. |
| Excretion | Primarily renal elimination of metabolites; <5% excreted unchanged. Biliary/fecal excretion accounts for a minor fraction. |
| Half-life | Plasma half-life approximately 1-2 hours for hydrocortisone; clinical effects persist longer due to local tissue retention. |
| Protein binding | Hydrocortisone is ~75-85% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd for hydrocortisone is approximately 0.3-0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: systemic absorption is minimal (<5%) through intact oral mucosa; inflamed mucosa may increase absorption. |
| Onset of Action | Topical: relief within minutes to hours; depends on formulation and condition. |
| Duration of Action | Topical: effects last 2-4 hours; dental paste provides prolonged contact up to 2 hours. |
| Molecular Weight | 404.5 |
Apply a small amount (approximately 2.5 cm) to the affected area as a thin film 2-3 times daily, after meals and at bedtime. Do not rub in. For adults, maximum duration of use is 7 days unless directed by a physician.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal with topical application. |
| Liver impairment | No dose adjustment required for hepatic impairment as systemic absorption is minimal with topical application. |
| Pediatric use | Children <12 years: Safety and efficacy not established; use only under physician supervision. Children ≥12 years: Same as adult dosing; apply a small amount (approximately 2.5 cm) 2-3 times daily. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. Caution in elderly due to potential for mucosal atrophy with prolonged use; limit duration to short-term (≤7 days). |
| 1st trimester | Hydrocortisone acetate ointment is generally considered low risk with minimal systemic absorption; however, avoid prolonged use on large areas. Topical corticosteroids should be used with caution in first trimester due to theoretical risk of orofacial clefts with systemic exposure. |
| 2nd trimester | Low risk with minimal systemic absorption. Use only if clearly needed and for short duration. No specific fetal risks reported with topical use in second trimester. |
| 3rd trimester | Low risk with minimal systemic absorption. Prolonged use or high potency may cause fetal growth restriction or adrenal suppression, but unlikely with low-potency hydrocortisone acetate. |
Clinical note
Comprehensive clinical and safety monograph for ORABASE HCA (ORABASE HCA).
| Placental transfer | Hydrocortisone acetate undergoes placental metabolism; minimal amounts of active drug cross the placenta due to first-pass metabolism in the placenta. Less than 1% of maternal dose reaches fetal circulation with topical use. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentUntreated fungal, viral, or bacterial oral infections (e.g., herpes simplex, candidiasis)Tuberculous or syphilitic oral lesions
| Precautions | Prolonged use may lead to oral candidiasis, Immunosuppression may mask infections, Systemic absorption possible with extensive application, Avoid use in presence of untreated oral infections |
| Food/Dietary | Avoid hot, spicy, acidic, or abrasive foods (e.g., chips, nuts) that may irritate lesions. Abstain from alcohol and carbonated beverages during treatment. No known systemic food interactions due to minimal absorption. |
| Clinical Pearls |
Loading safety data…
| Minimal systemic absorption from topical oral application; unlikely to result in clinically relevant levels in breast milk. Use only on small areas for short periods. No special precautions needed. |
| Lactation Rating | L1: Safe |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used in limited amounts; however, systemic absorption can occur. Animal studies with corticosteroids have shown teratogenicity, but no adequate human studies for ORABASE HCA. Use only if benefit outweighs risk; avoid prolonged use, especially in first trimester. |
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother if used long-term or on large areas. No specific fetal monitoring required with short-term topical use. |
| Fertility Effects | No known effects on fertility with topical use. Systemic corticosteroids may affect fertility, but topical application in oral doses is unlikely to have significant impact. |
| Contains hydrocortisone acetate 0.5% in an adhesive oral base. Apply after meals and at bedtime; avoid eating immediately after application to maximize contact time. Not for systemic use; minimal absorption through oral mucosa. Limit use to 7-10 days to avoid mucosal atrophy or candidiasis. For severe or persistent lesions, consider alternative diagnosis (e.g., autoimmune disease). |
| Patient Advice | Apply a small amount (about 1/4 inch) to the affected area after meals and at bedtime. · Do not eat or drink for at least 30 minutes after application to allow the paste to adhere. · Do not rub or massage the paste into the lesion; gently dab it on. · Avoid using this medication for more than 10 days unless directed by your doctor. · If symptoms worsen or do not improve after 7 days, contact your healthcare provider. · Store at room temperature away from moisture and heat. |